Capecitabine/irinotecan or capecitabine/oxaliplatin in combination with bevacizumab is effective and safe as first-line therapy for metastatic colorectal cancer: a randomized phase II study of the AIO colorectal study group.

@article{Schmiegel2013CapecitabineirinotecanOC,
  title={Capecitabine/irinotecan or capecitabine/oxaliplatin in combination with bevacizumab is effective and safe as first-line therapy for metastatic colorectal cancer: a randomized phase II study of the AIO colorectal study group.},
  author={Wolff H. Schmiegel and Ank Reinacher-Schick and D. Arnold and Stephan Kubicka and Werner Freier and Gerd Dietrich and Michael Geissler and Susanne Hegewisch-Becker and Andrea Tannapfel and Miki Pohl and Axel Hinke and Hans-Joachim Schmoll and Ullrich Graeven},
  journal={Annals of oncology : official journal of the European Society for Medical Oncology},
  year={2013},
  volume={24 6},
  pages={1580-7}
}
BACKGROUND This randomized phase II trial investigated the efficacy and safety of capecitabine/oxaliplatin (CapOx) plus bevacizumab and dose-modified capecitabine/irinotecan (mCapIri) plus bevacizumab as first-line therapy in patients with metastatic colorectal cancer (mCRC). PATIENTS AND METHODS Patients received bevacizumab 7.5 mg/kg with oxaliplatin 130 mg/m(2)/day 1 plus capecitabine 1000 mg/m(2) bid/days 1-14 or with irinotecan 200 mg/m(2)/day 1 plus capecitabine 800 mg/m(2) bid/days 1… CONTINUE READING